CBSE Class 12 Biology exam 2026: Faculty insights on important chapters, diagrams and revision

The CBSE Class 12 Biology exam will be held on March 27, 2026. It is normal to feel excited or a little nervous. Biology is ...

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollmentCHARLESTOWN, Mass., Jan. 12 ...

SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan

PRNewswire/ -- (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited ...

Tiny Sloth Bear Cubs Are Stealing Hearts at the Smithsonian Zoo

For the Smithsonian National Zoo and Conservation Biology Institute (NZCBI), Christmas came early in 2025. Zookeepers were ...

Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD

The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...

Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients

Bristol-Myers Squibb Company (NYSE: BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers ...
The Manila Times

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Opera…

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency ...

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating ...

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on ...

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on ...
TMCnet

Settlement Announced in 23andMe Cyber Security Incident Litigation.

A Settlement has been reached with 23andMe, Inc. (now known as "Chrome") in a class action lawsuit over the Cyber Security Incident announced by 23andMe in October 2023, which resulted in the ...

Solid Biosciences Inc.: Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular ...
ScienceAlert on MSN

Common Pesticide Exposure Linked With 2.7x Risk of Parkinson's Disease

Long-term exposure to the pesticide chlorpyrifos, widely used on US farms, has been linked to a more than 2.5-fold increase ...